Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2000 2
2001 5
2002 3
2003 3
2004 1
2006 1
2007 1
2008 2
2009 2
2010 3
2011 1
2012 1
2013 1
2014 3
2015 3
2016 6
2017 6
2018 8
2019 7
2020 6
2021 5
2022 1
2023 8
2024 3
2025 7
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. Among authors: tieghi a. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
De Stefano V, Passamonti F, Palandri F, Ramundo F, Rossi E, Betti S, Fagiolo L, Guglielmelli P, Abagnale DP, Pugliese N, Cattaneo D, Iurlo A, Branzanti F, Dedola A, Catellani H, Tieghi A, Basso M, Calistri E, Elli EM, Masselli E, Morsia E, Benevolo G, Breccia M, de Fazio V, Di Perna M, Marchetti M, Santoro M, Tafuri A, Castiglioni C, Rotella C, Siragusa S, Vannucchi AM; PROSPERO Study group. De Stefano V, et al. Among authors: tieghi a. Ann Hematol. 2025 Jul;104(7):3553-3566. doi: 10.1007/s00277-025-06466-z. Epub 2025 Jul 18. Ann Hematol. 2025. PMID: 40679584 Free PMC article. Review.
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, Beggiato E, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Scalzulli E, D'Agostino D, Caserta S, Nardo A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Palumbo GA, Breccia M, Elli EM, Bonifacio M. Palandri F, et al. Among authors: tieghi a. Ann Hematol. 2025 Jan;104(1):241-251. doi: 10.1007/s00277-025-06204-5. Epub 2025 Jan 20. Ann Hematol. 2025. PMID: 39831987 Free PMC article.
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.
Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Filì C, Carella AM, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Curti A, Luppi M, Ingrosso C, Martelli MP, Cuneo A, Albano F, Mulè A, Tafuri A, Cudillo L, Tieghi A, Fracchiolla NS, Capelli D, Trisolini SM, Alati C, La Sala E, Maurillo L, Del Principe MI, Irno Consalvo MA, Divona MD, Ottone T, Cerretti R, Sconocchia G, Voso MT, Fazi P, Vignetti M, Buccisano F. Venditti A, et al. Among authors: tieghi a. Blood Adv. 2024 Aug 27;8(16):4410-4413. doi: 10.1182/bloodadvances.2024013182. Blood Adv. 2024. PMID: 38968139 Free PMC article. No abstract available.
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E. Palandri F, et al. Among authors: tieghi a. Leuk Res. 2025 Jul;154:107719. doi: 10.1016/j.leukres.2025.107719. Epub 2025 May 27. Leuk Res. 2025. PMID: 40460507 No abstract available.
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT. Palandri F, et al. Among authors: tieghi a. Cancer. 2025 Sep 1;131(17):e70062. doi: 10.1002/cncr.70062. Cancer. 2025. PMID: 40839414 Free PMC article.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: tieghi a. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.
Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, Tiribelli M, Cavazzini F, D'Addio A, Tieghi A, Farina M, Cavalca F, Dedola A, Heidel FH, Palumbo GA, Rossi E, Branzanti F, De Stefano V. Palandri F, et al. Among authors: tieghi a. Leukemia. 2025 Aug;39(8):1928-1936. doi: 10.1038/s41375-025-02646-y. Epub 2025 May 28. Leukemia. 2025. PMID: 40437171 Free PMC article.
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.
Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Iurlo A, Lemoli RM, Cilloni D, Bocchia M, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F. Palandri F, et al. Among authors: tieghi a. Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):e524-e532.e3. doi: 10.1016/j.clml.2025.02.015. Epub 2025 Mar 4. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40133140
76 results